]>
IRCT20160722029027N9 IRCT 2019-12-04 Shahid Beheshti University of Medical Sciences Effect of platelet rich plasma (PRP) improving pregnancy outcome Effect of platelet rich plasma (PRP) on improving pregnancy outcome in recurrent pregnancy loss patients a randomized clinical trial pilot study 2017-04-21 anticipated 50 Complete https://irct.ir/trial/41765 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be done by generating random numbers in Excel software. 1. In a column of Excel we enter 25 samples in each group. 2. In the next column we generate random numbers using the following command: RAND () 3. After sorting the generated random numbers, a random list will be generated according to which people will be assigned to two groups, Blinding description: Blindness will be such that the patient will not know what treatment she will receive. Also, the researcher who records the results will not be aware of the type of treatment applied to the patient. 2 Noninflammatory disorders of female genital tract. Intervention 1: Intervention group: Initiation of ovarian stimulation will start on day 3 of the menstrual cycle. Follicular monitoring will perform using serial ultrasonography. When the diameter of follicles reached approximately 14 mm, the GnRH antagonist will start. When at least three follicles >17 mm diameter visualizes in the ovaries, ovulation trigger will carry out using 10000 IU of human chorionic gonadotropin (hCG). The oocytes will aspirate from the ovaries 36 hours later. After intra-cytoplasmic sperm injection, intrauterine administration of platelet rich plasma (PRP) will be performed 48 hours before embryo transfer. Autologous PRP will be prepared during the 2-step procedure. Prepared PRP (5 CC) will be inoculated into the uterus. Finally, blastocyst embryos will transfer to the uterus. Intervention 2: Control group: Initiation of ovarian stimulation will start on day 3 of the menstrual cycle. Follicular monitoring will perform using serial ultrasonography. When the diameter of follicles reached approximately 14 mm, the GnRH antagonist will start. When at least three follicles >17 mm diameter visualizes in the ovaries, ovulation trigger will carry out using 10000 IU of human chorionic gonadotropin (hCG). The oocytes will aspirate from the ovaries 36 hours later. After intra-cytoplasmic sperm injection, blastocyst embryos will transfer to the uterus. Yes - There is a plan to make this available What will be shared: Only information about the main outcome can be shared. When: Without restriction To whom: All researchers Conditions: With permission from the responsible author Where to obtain: Email to the responsible author How to obtain: Email to the responsible author Comments:
public Teibeh Hashemi
Shabih Khani Hospital .Shahid Beheshti St
Kashan Iran (Islamic Republic of) 8714715555 +98 31 5546 0180 hashemit89@yahoo.com Shahid Beheshti University of Medical Sciences scientific Leila Nazari
Taleghani hospital, Yaman st., Velenjak, Chamran highway
Tehran Iran (Islamic Republic of) 1983969411 +98 21 2243 2558 nazari@sbmu.ac.ir Shahid Beheshti University of Medical Sciences Iran (Islamic Republic of) Women under 40 years 30>BMI At least two pregnancy loss no limit 40 years Female Immunologic disorder Anti phospholipid syndrome Hormonal disturbance Chromosomal disorder Congenital and acquired uterine disorder Hematological disturbance Treatment - Other N/A Intervention group: Initiation of ovarian stimulation will start on day 3 of the menstrual cycle. Follicular monitoring will perform using serial ultrasonography. When the diameter of follicles reached approximately 14 mm, the GnRH antagonist will start. When at least three follicles >17 mm diameter visualizes in the ovaries, ovulation trigger will carry out using 10000 IU of human chorionic gonadotropin (hCG). The oocytes will aspirate from the ovaries 36 hours later. After intra-cytoplasmic sperm injection, intrauterine administration of platelet rich plasma (PRP) will be performed 48 hours before embryo transfer. Autologous PRP will be prepared during the 2-step procedure. Prepared PRP (5 CC) will be inoculated into the uterus. Finally, blastocyst embryos will transfer to the uterus. Control group: Initiation of ovarian stimulation will start on day 3 of the menstrual cycle. Follicular monitoring will perform using serial ultrasonography. When the diameter of follicles reached approximately 14 mm, the GnRH antagonist will start. When at least three follicles >17 mm diameter visualizes in the ovaries, ovulation trigger will carry out using 10000 IU of human chorionic gonadotropin (hCG). The oocytes will aspirate from the ovaries 36 hours later. After intra-cytoplasmic sperm injection, blastocyst embryos will transfer to the uterus. Clinical pregnancy. Timepoint: 5-7 weeks of gestation. Method of measurement: Ultrasonography. Ongoing pregnancy. Timepoint: 20 weeks of gestation. Method of measurement: Ultrasonography. Live birth. Timepoint: 9 months after embryo transfer. Method of measurement: Visualization. Shahid Beheshti University of Medical Sciences Approved 2019-10-01 Ethics committee of Shahid Beheshti University of Medical Sciences Velenjak, Yaman St, Chamran highway Tehran Tehran Iran (Islamic Republic of)